LXH-254 and Erlotinib Combination Therapy Data for KRAS-Driven Pancreatic Cancer

Jakob Brandstetter's 67.5 KB Excel file contains preclinical data evaluating a combination therapy for pancreatic cancer. The dataset likely contains results from in vitro and in vivo studies assessing cell proliferation, death, and signaling protein phosphorylation. Findings from 2026 indicate the EGFR inhibitor erlotinib and pan-RAF inhibitor LXH-254 combination did not improve survival in murine models despite inhibiting MAPK signaling.

Use Cases

• Analyze anti-proliferative effects of LXH-254 and erlotinib based on in vitro cell proliferation data
• Evaluate MAPK signaling inhibition based on phosphorylation levels of key proteins
• Compare preclinical model outcomes based on data from orthotopic murine and genetically engineered KPC mice

Strengths

• Data is focused on the KRAS G12D mutation, present in approximately 90% of pancreatic tumors
• Includes results from both in vitro cell line studies and in vivo murine models
• File is openly licensed under CC-BY-4.0

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data scale is limited to 67.5 KB, suggesting a focused experimental dataset

Provenance

Source

figshare

Collection Method

Likely contains experimental data from preclinical studies on pancreatic cancer cell lines and mouse models.

Freshness

Last updated 2026-04-24 17:35:46; freshness should be verified